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Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the synthesis of
nicotinamide mononucleotide (NMN) from nicotinamide (NM) and 5′-phosphoribosyl1′-pyrophosphate (PRPP). It catalyzes the key rate-limiting step in the nicotinamide
adenine dinucleotide (NAD+) synthetic salvage pathway, plays a central role in
cellular bioenergetics,1,2 and may indirectly control a number of signaling pathways that depend on NAD levels, such as poly (ADP-ribose) polymerase (PARP)
and sirtuin activation.2 A secreted form of NAMPT was originally identified as
an extracellular proinflammatory cytokine that could induce cellular expression
of inflammatory cytokines, such as tumor necrosis factor α (TNFα), interleukin
(IL)1β and IL6, and promote pre-B-cell colony formation.3,4 Lymphocytes, dendritic
cells, monocytes, and macrophages express NAMPT when presented with inflammatory stimuli.1,5,6 Thus, NAMPT, either via the NAD salvage pathway or by other
unknown mechanisms relating to its secreted form, may modulate innate or acquired
immune functions.
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Abstract: Our previous study indicated that overexpression of nicotinamide phosphoribosyltransferase (NAMPT) aggravated acute lung injury, while knockdown of NAMPT expression
attenuated ventilator-induced lung injury. Recently, we found that meta-carborane-butyl3-(3-pyridinyl)-2E-propenamide (MC-PPEA, MC4), in which the benzoylpiperidine moiety
of FK866 has been replaced by a carborane, displayed a 100-fold increase in NAMPT inhibition over FK866. Here, we determined the effects of MC4 and FK866 on cecal ligation and
puncture (CLP) surgery-induced sepsis in C57BL/6J mice. MC4 showed stronger inhibitory
effects than FK866 on CLP-induced mortality, serum tumor necrosis factor α (TNFα) levels,
pulmonary myeloperoxidase activity, alveolar injury, and interleukin 6 and interleukin1β messenger RNA levels. In vitro cell permeability and electric cell–substrate impedance sensing
assays demonstrated that MC4 inhibited TNFα- and thrombin-mediated pulmonary endothelial
cell permeability better than FK866. MC4 also exerted more potent effects than FK866, at
concentrations as low as 0.3 nM, to attenuate TNFα-mediated intracellular cytokine expression,
nicotinamide adenine dinucleotide (NAD+) and its reduced form NADH levels, and nuclear
factor kappa B p65 phosphorylation and nuclear translocation in A549 cells. Our results
strongly suggest that the newly developed MC4 is a more potent suppressor of CLP-induced
pulmonary inflammation and sepsis than FK866, with potential clinical application as a new
treatment agent for sepsis and inflammation.
Keywords: NAMPT, pulmonary inflammation, sepsis
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Our previous study indicated that overexpression of
NAMPT aggravated acute lung injury,7 while knockdown
of NAMPT expression attenuated ventilator-induced lung
injury.8 Emerging data have implicated NAMPT in the
pathogenesis of a number of different human diseases, particularly in the field of cancer and inflammation.9 NAMPT
was upregulated in immune cells, including monocytes,
macrophages, dendritic cells, T cells, and B cells, as
well as in hematopoietic precursors during granulocyte
colony-stimulating factor (G-CSF)-induced granulocytic
differentiation.1,10,11 NAMPT levels have also been found
being elevated in the systemic circulation of patients suffering from diseases with inflammatory components, such as
type 2 diabetes,12 acute pancreatitis,13 osteoarthritis,14 sepsis,15
atherosclerosis,16 and psoriasis.17
The search for novel antitumor drugs has led to the
identification of inhibitors of NAMPT. FK866 (also known
as APO866) is the first known specific and highly potent
small-molecule inhibitor of NAMPT. Inhibition of NAMPT
by administration of FK866 ameliorates inflammatory
symptoms in animal models of arthritis, endotoxic shock,
autoimmune encephalitis, and spinal cord injury.10,11,18,19
Unfortunately, Phase II clinical trials have identified severe
dose-limiting adverse effects of FK866, such as thrombocytopenia, lymphopenia, and anemia.20 Thus, development of
more potent NAMPT inhibitors remains an area of strong
interest in pharmaceutical research. In our previous study,
the new NAMPT inhibitor analog, meta-carborane-butyl3-(3-pyridinyl)-2E-propenamide (MC-PPEA, MC4), was
synthesized by replacing the benzoylpiperidine moiety
in FK866 with meta-carborane.21 The carborane moiety
proved superior to benzoylpiperidine, owing to the size and
hydrophobicity of carboranes, as well as their potential to
form strong dihydrogen bonds with available amino acid
residues. This new inhibitor, MC4, exhibits up to 10-fold
greater anti-proliferative activity against cancer cells in vitro
and a 100-fold increase in NAMPT inhibition than FK866.21
This new carborane-based agent is among the most potent
inhibitors reported to date for NAMPT. However, this new
inhibitor has not yet been applied to suppress inflammation
via its inhibition of NAMPT function. We hypothesize that
MC4 would be a much stronger suppressor of inflammation than FK866 since MC4 is a much stronger inhibitor of
NAMPT, a known novel inflammatory cytokine.22,23 To test
the hypothesis, we have engaged in this comparative study
between MC4 and FK866 to evaluate their therapeutic efficacies in the treatment of both cecal ligation and puncture
(CLP)-induced sepsis and pulmonary inflammation and
630
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to investigate the molecular mechanisms underlying their
differences both in vivo and in vitro.

Materials and methods
Mice, CLP-induced sepsis,
myeloperoxidase (MPO) activity assay, and
histological examination of mouse lungs
Eight- to 12-week-old male C57BL/6J mice (body weight
[BW]: 25–31 g; The Jackson Laboratory, Catalog#: 000664)
were housed in accordance with the institutional animal care
regulations of the University of Missouri Kansas City Institutional Animal Care and Use Committee (IACUC) with an open
access to standard chow and water. Animal experiments were
approved by the University of Missouri Kansas City IACUC.
FK866 and MC4 were dissolved in dimethyl sulfoxide (DMSO)
and diluted further with phosphate-buffered saline (PBS) before
being applied to mice. In the preventative study, mice received
three intraperitoneal injections of 10 mg/kg FK866 or MC4 at
24, 16, and 2 h prior to CLP surgery according to Esposito et
al.19 For the therapeutic study, mice were administered once
10 mg/kg FK866 or MC4 by intraperitoneal injection immediately after the CLP surgery. CLP surgery was performed as
described by Rittirsch et al.24 Briefly, mice were anesthetized
by 60 mg/kg BW (IP) pentobarbital. Under sterile conditions,
a 1.5 cm incision was made in the lower abdominal region to
expose the cecum. The distal portion of the cecum was ligated
1.5 cm from the end with a 4–0 silk suture and punctured once
with a 16-G needle. The cecum was squeezed to place a small
portion of its content (bacteria and feces) into the peritoneum
before it was replaced in the peritoneal cavity. The peritoneal
wall and skin were closed with double sutures. The mice were
resuscitated with a subcutaneous injection of sterile saline
(1 mL). As a control, mice were sham-operated as described
earlier, except that the cecum was neither ligated nor perforated. After the procedure, the mice had an accessible source
of water and food ad libitum. The mice were either observed
for 6 days for survival experiment or euthanized 24 h after
CLP for TNFα and histology analyses. Serum was extracted
from drawn blood and stored at -80°C, and TNFα levels were
measured using a commercial kit (Catalog#: MTA00B; R&D
Systems Inc., Minneapolis, MN, USA). The right lobe of the
lung was isolated, snap frozen in liquid nitrogen, and stored
at -80°C for RNA isolation and MPO activity assay (Catalog#:
MAK068; Sigma-Aldrich, St Louis, MO, USA) according to
the manufacturer’s procedure. The left lung lobe was removed,
preserved in formalin, embedded in paraffin, cut at 5 μm thickness, and stained with hematoxylin and eosin (H&E). Lung
histopathology was examined in a blinded manner as to what
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group/mouse was reviewed using a modification of a histologic
scoring system described by Londhe et al.25 In each section,
10 fields were examined at 400× magnification and randomly
scored for 1) interstitial edema, 2) alveolar edema, 3) hemorrhage, and 4) leukocytes and neutrophil infiltrates. The scores
from each field were averaged and presented on a scale of 0–4
(0 being none present; 4 being severe and diffuse throughout
the chosen field). The histological lung injury scores present
the sum of the mean injury subtype scores for each condition
on a scale of 0–16.26 Two sections of each lung and four lungs
for each group were scored.

Chemicals and antibodies
FK866 was obtained from Cayman Chemical (Ann Arbor,
MI, USA; Catalog#: 13287). MC-PPEA (MC4) was synthesized as described previously.21 Rabbit anti-human nuclear
factor kappa B (NFκB) p65 (D14E12) XP monoclonal antibody (Catalog#: 8242) and phospho-NFκB p65 (Ser536)
(93H1) rabbit monoclonal antibody (Catalog#: 3033) were
purchased from Cell Signaling Technology (Beverly, MA,
USA). Rabbit anti-human GAPDH monoclonal antibody
(Catalog#: G9545) was from Sigma-Aldrich. Rabbit antihuman PBEF/NAMPT polyclonal antibody was from Bethyl
Laboratories, Inc. (Montgomery, TX, USA; Catalog#:
A300-372A). Recombinant human TNFα was from R&D
Systems Inc. (Catalog#: 210-TA). Superscript III Reverse
Transcriptase (Catalog#: 18080044) and Platinum Taq
DNA Polymerase (Catalog#: 10966018) were from Thermo
Fisher Scientific (Waltham, MA, USA). Sources of other key
reagents are specified in the relevant text.

Cell culture
Human A549 cells, a lung carcinomatous type II alveolar epithelial cell line, were obtained from ATCC (Manassas, VA,
USA; Catalog#: CCL-185™) and maintained in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with 10%
fetal bovine serum, 2 mM glutamine, and 1% penicillin/
streptomycin. Human lung microvascular endothelial cells
(HMVEC-L) were obtained from Lonza (Walkersville,
MD, USA; Catalog#: CC-2527) and maintained in EBM-2
endothelial media (Catalog#: CC-3162; Lonza). All cells
were cultured at 37°C in a humidified atmosphere of 5% CO2.
Cells (passage: 15–23) from each primary flask were detached
with 0.05% trypsin, resuspended in fresh culture medium,
and seeded into 6-well plates for various experimental conditions followed by Western blot and reverse transcriptionpolymerase chain reaction (RT-PCR) analysis or seeded into
the culture inserts for in vitro cell permeability assays.
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In vitro cell permeability assays
In vitro cell permeability assays were carried out according to the protocol of the CHEMICON In Vitro Vascular
Permeability Assay kit (Catalog#: ECM644; Millipore,
Billerica, MA, USA). Briefly, cells (5×105) were seeded
into the culture inserts of permeability chambers that were
coated with collagen and incubated at 37°C for 24 h until
a monolayer was formed. After the cells were starved for
serum for 2 h, TNFα (50 ng/mL), TNFα with MC4 (30, 3,
0.3 nM), or TNFα with FK866 (30, 3, 0.3 nM) was added,
cells were incubated for another 18 h at 37°C, followed by
addition of 150 μL of FITC-Dextran to each insert for 5 min
at room temperature (RT), and then 100 μL of the solution
in the bottom chamber was transferred to a 96-well plate.
Absorbance at 485 and 530 nm was measured in a TriStar
Multimode Reader (LB 941, Berthold Technologies GmbH &
Co. KG, Bad Wildbad, Germany). Reagent control wells were
treated with basal medium or growth medium only. Blank
inserts without plated cells were also included as controls.

Measurement of transendothelial
electrical resistance (TER)
Cellular barrier properties were measured using an electrical
cell–substrate impedance sensing system (ECIS Ztheta;
Applied Biophysics, Troy, NY, USA). HMVEC-L were
seeded onto array chambers containing 40 gold electrodes
per well (8W10E+, Applied Biophysics) pretreated with
10 mM cysteine and coated with fibronectin (20 µg) according to the manufacturers’ specifications. The experiments
were initiated when the cells reached confluence, as determined by a capacitance of ,10 at 32,000 Hz. HMVEC-L
were starved for 2 h, then pretreated with MC4 (0.3 nM) or
FK866 (0.3 nM) for 2 h prior to treatment with 0.5 units/mL
of thrombin (Sigma-Aldrich; Catalog#: T4393). The data are
presented as normalized resistance vs time.

Isolation of RNA, RT-PCR analysis, and
Western blot analysis
Total RNA was isolated from A549 cells with a mirVana™
miRNA Isolation Kit (Catalog#: AM1561; Thermo Fisher
Scientific) as described previously.27 RT-PCR was performed
with Superscript III (Catalog#: 11752-250; Thermo Fisher
Scientific) with specific primers (Table 1) synthesized by
Integrated DNA Technologies (Coralville, IA, USA). PCR
products were separated on 3% agarose gels and stained with
ethidium bromide (0.5 μg/mL). The gel image was acquired
using an Alpha Imager and analyzed by the AlphaEase™ Stand
Alone Software (Alpha Innotech Corporation, San Leandro,
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Table 1 Primers and product size
Gene

5′ Primers

3′ Primers

Size (bp)

Accession no

IL6
IL8
IL16
CCR3
PBEF
β-Actin
mβ-Actin
mIL1β
mIL8
mIL6

AAATGCCAGCCTGCTGACGAAG
ATGACTTCCAAGCTGGCCGT
TAGTGCCAAGGTACAAACAGGTG
CAAGATTTGAGGCTGGGAAG
AAGCTTTTTAGGGCCCTTTG
CAAACATGATCTGGGTCATCTTCTC
TGCTGTCCCTGTATGCCTCT
GTGTGACGTTCCCATTAGACAAC
CTAGGCATCTTCGTCCGTCC
GGGACTGATGCTGGTGACAA

AACAACAATCTGAGGTGCCCATGCTAC
CCTCTTCAAAAACTTCTCCACAACC
GGGTCTCAAACTCAGATGCCTAT
AGCTTTTTCACAGAGCAGGC
AGGCCATGTTTTATTTGCTGACAAA
GCTCGTCGTCGACAACGGCTC
AGGTCTTTACGGATGTCAACG
TGAGGTGCTGATGTACCAGTT
CAGAAGCTTCATTGCCGGTG
TCTGCAAGTGCATGATCGTT

123
297
280
228
319
487
471
382
282
210

NM_00600
NM_000584
NM_172217
NM_001837
NM_005746
NM_001101
NM_007393.3
NM_008361.3
NM_011339.2
NM_031168.1

Note: m indicates mouse gene primers.
Abbreviations: IL, interleukin; PBEF, pre-B-cell colony-enhancing factor.

CA, USA). Western blots were performed as described
previously.28 Band images were acquired using an Alpha
Imager and analyzed by the AlphaEase Stand Alone Software as a measure of assayed protein level.

Enzyme-linked immunosorbent assay
(ELISA) for cell-based human IL6
Intracellular human IL6 levels were determined using a
Human IL-6 ELISA Kit (Catalog#: RAB0307; SigmaAldrich). Briefly, A549 cells (3×105) were seeded into 6-well
plates and incubated overnight at 37°C. After incubation in
serum-free media for 2 h, the cells were treated with or without TNFα (50 ng/mL), TNFα with MC4 (30, 3, 0.3 nM), or
TNFα with FK866 (30, 3, 0.3 nM) for another 6 h, at which
time the cells were lysed in preparation for the ELISA.

Immunofluorescence imaging of nuclear
translocation of NFκB in A549 cells
A549 cells were seeded on poly-l-lysine-coated glass slides
(Catalog#: p0425; Sigma-Aldrich) and cultured in a 35 mm
Petri dish with 3 mL of media at 37°C in a humidified atmosphere of 5% CO2. After 24 h, cells were pre-incubated with
or without 0.3 nM MC4 or FK866 for 2 h. Then, cell layers
were treated with TNFα (10 ng/mL), TNFα plus 0.3 nM
of MC4, or TNFα plus 0.3 nM of FK866 for an additional
20 min. Cell layers were washed three times with 5 mL PBS
for 5 min each and fixed in 4% paraformaldehyde for 15 min
at RT. Afterward, the slides were rinsed three times in 2 mL
of PBS for 5 min each, followed by 60 min in blocking buffer
(PBS/5% normal goat serum; Catalog#: 5245; Cell Signaling Technology). The slides were incubated overnight at
4°C with NFκB antibody (1:500) in antibody dilution buffer
(PBS/1% BSA/0.3% Triton™ X-100) followed by three
washes with PBS for 5 min each. Incubation of the slides in
diluted anti-rabbit IgG (H+L), F(ab′)2 fragment (Alexa Fluor®
488 Conjugate) with 1:50 antibody dilution buffer for 1 h at
632
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RT in the dark. The slides were then washed (3×) with PBS,
prior to attaching coverslips with Prolong Gold Antifade
Reagent (Catalog#: 9071; Cell Signaling Technology) with
4,6-diamidino-2-phenylindole (DAPI). The slides were cured
for 24 h at RT prior to microscopy (Olympus, U-TV0.5xC-3,
Center Valley, PA, USA).

Intracellular NAD+ plus NADH-level assays
and MPO activity assay
Intracellular NAD+ plus NADH (NAD/NADH) concentration
assays were performed according to the manufacturer’s protocol for an NAD+/NADH Cell-Based Assay Kit (Catalog#:
600480; Cayman Chemical) with minor modifications. Briefly,
A549 cells were seeded in 96-well plates (3×104 cells/well in
120 µL of culture medium) and incubated overnight in a CO2
incubator at 37°C. The cells were starved in serum-free media
for 2 h, treated with or without TNFα (50 ng/mL) or TNFα
plus indicated concentrations of MC4 or FK866 for another
6 h, prior to the measurement of NAD+/NADH levels.

Statistics

All data were expressed as mean ± standard deviation (SD).
Differences among treatments were assessed by the one-way
analysis of variance (ANOVA) followed by the Holm–Sidak
post hoc test. IBM SPSS 23 was used to perform logrank
and Breslow tests for survival analysis. Differences between
groups were considered statistically significant at P,0.05.

Results
Inhibitory effects of MC4 and FK866
on CLP-induced mouse mortality,
serum TNFα levels, pulmonary MPO
activities, pulmonary IL6 and IL1β mRNA
expressions
The NAMPT inhibitor, FK866, has been shown previously
to have an anti-inflammatory function in vivo. In this study,
Drug Design, Development and Therapy 2017:11
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by logrank (P=0.24) and Breslow (P=0.23) tests, when compared to the vehicle-treated CLP mice (Figure 1A).
To investigate the mechanisms of protect effects of MC4
and FK866, we detected the CLP-induced TNFα levels in
mouse sera, a key inflammatory marker. In sham mice,
the mean serum TNFα level was 4.13±5.1 pg/mL. In mice
administrated with DMSO, CLP increased serum levels to
54.7±5.6 pg/mL, while in mice administrated with FK866 or
MC4, CLP-induced TNFα levels in serum decreased significantly to 32.99±4.5 pg/mL (P=0.039) and 17.81±3.2 pg/mL
(P=0.007), respectively (Figure 1B).
Pulmonary tissue MPO activity is an indicator of neutrophil
infiltrates into lung parenchyma during pulmonary inflammation, a frequent sequelae of CLP-induced sepsis. We determined lung MPO activity after the treatment of either FK866
or MC4 in CLP-operated mice (Figure 1C). The mean MPO
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Figure 1 Inhibitory effects of MC4 and FK866 on CLP-induced mortality and cytokine levels.
Notes: C57BL/6J mice were treated with 10 mg/kg body weight of MC4 and FK866 via intraperitoneal injection. Mice were dosed 3× (24, 16, and 2 h) prior to the CLP
surgery. (A) Survival curve of CLP mice. FK866 (n=16), MC4 (n=16), DMSO control (n=16), and sham (n=3). (B) After 24 h of CLP, mouse serum was assayed for TNFα
levels. (C) After 24 h of CLP, MPO activities were assayed on 10–20 mg of isolated lung tissues. (D) Representative images of IL6 and IL1β mRNA levels in lung tissues
measured by semi-quantitative RT-PCR. B-Actin (ActB) expression was presented as control. (E) Densitometry analysis of CLP-induced mRNA expressions normalized to
β-actin- and DMSO-treated controls. Bars are mean ± SD, n=7. *P,0.05, **P,0.01 vs DMSO-treated control mice, #P,0.05 vs FK866-treated mice.
Abbreviations: MC4, meta-carborane-butyl-3-(3-pyridinyl)-2E-propenamide; CLP, cecum ligation and puncture; DMSO, dimethyl sulfoxide; TNFα, tumor necrosis factor α;
MPO, myeloperoxidase; IL, interleukin; mRNA, messenger RNA; SD, standard deviation; RT-PCR, reverse transcription polymerase chain reaction.
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activities were 4.20±0.7, 2.49±1.2, and 1.19±0.3 microunits/g
tissue for treatments with DMSO, FK866, and MC4, respectively. This finding suggested that MC4 was a more potent
inhibitor of neutrophil infiltrates in the inflammatory mouse
lungs than FK866 (P=0.03). In sham mice, the MPO activity
(0.47±0.14 microunits/g) was much lower than CLP mice.
We also directly compared the inhibitory effects of
FK866 and MC4 on the expression of pulmonary inflammatory cytokines. Compared with DMSO-treated control mice,
the relative mRNA levels of IL6 were decreased significantly
to 0.62±0.2 (P=0.047) and 0.39±0.2 (P=0.021) in FK866and MC4-treated mice, respectively (Figures 1D and 1E).
IL1β mRNA levels also decreased upon FK866 (0.74±0.2,
P=0.081) and MC4 (0.44±0.1, P=0.037) treatment. The
IL1β mRNA levels in MC4-treated mice were decreased

$

significantly when compared to both the DMSO-treated and
FK866-treated mice. IL6 and IL1β mRNA levels were not
detectable in sham-operated mice (data not shown).

Therapeutic effects of FK866 and MC4
on CLP-induced serum TNFα levels and
lung injury in mice
To test the potential therapeutic effect of both FK866 and
MC4 on CLP-induced sepsis, mice were administered with
FK866 and MC4 (10 mg/kg) via a single intraperitoneal
injection immediately following CLP. After 24 h, serum
TNFα levels were significantly lower in the MC4 treatment
group (39.8±7.1 pg/mL) compared to the vehicle control
(83.6±32.3; P=0.028) and FK866 (63.6±18.8 pg/mL;
P=0.043) groups, respectively (Figure 2A). The TNFα levels
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Figure 2 Therapeutic effects of FK866 and MC4 on CLP-induced sepsis.
Notes: C57BL/6J mice were treated with 10 mg/kg body weight of FK866 and MC4 via an intraperitoneal injection immediately after the CLP or sham surgery. After 24 h
of CLP, (A) mouse blood was drawn and serum was assayed for TNFα levels. (B) LISs represent the sum of the mean injury subtype scores for each condition on a scale
of 0–16. (C) H&E staining of representative lung tissue sections. Sham mice show normal lung histology; CLP mouse lung shows injuries in lung tissue: alveoli filled with
proteinaceous fluid, septal thickening, and interstitial lymphocytic and neutrophilic infiltration. Results are mean ± SD, n=6, *P,0.05 vs DMSO-treated mice; #P,0.05 vs
FK866-treated mice.
Abbreviations: MC4, meta-carborane-butyl-3-(3-pyridinyl)-2E-propenamide; CLP, cecum ligation and puncture; TNFα, tumor necrosis factor α; LIS, lung injury score; H&E,
hematoxylin and eosin; SD, standard deviation; DMSO, dimethyl sulfoxide.
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in FK866-treated mice were also lower than the control
group, but without statistical significance (P=0.21).
Histological examination by H&E staining of sections from vehicle control lung tissue after CLP showed
increased damage of the lung tissue, including alveoli filled
with proteinaceous fluid, septal thickening, and interstitial
neutrophilic and lymphocytic infiltration relative to the
sham-operated control mice that presented with normal
lung tissue structure (Figures 2B and 2C). FK866 and
MC4 treatment attenuated the CLP-induced injury in lung
tissues, with MC4 treatment demonstrating more potent
therapeutic effects than FK866 (Figure 2C). Mortality was
not observed in any of the four treatment groups (sham,
CLP + DMSO, CLP + FK866, and CLP + MC4) within
the 24 h time frame and the selected dosages (10 mg/kg)
of the drug treatments.
The lung injury score (LIS) was used to evaluate neutrophil infiltration, hemorrhage, interstitial edema, and alveolar
wall damage in histological sections of lungs from mice
treated therapeutically with DMSO, FK866, and MC4 following CLP. Consistent with the observation in H&E staining
in lung tissue (Figure 2C), the CLP + DMSO mice presented
with the highest LIS (8.7±1.9) compared to the CLP + FK866
(6.4±2.3), CLP + MC4 (4.3±1.7), and sham mice (1.9±0.6)
(Figure 2B). MC4 treatment following CLP resulted in significantly lowered LIS scores compared to either CLP + DMSO
(P=0.017) or CLP + FK866 (P=0.031). Although FK866
treatment following CLP also lowered the LIS compared

$

To investigate further the mechanisms by which MC4 and
FK866 inhibit inflammation, we performed in vitro monolayer cell permeability assays in HMVEC-L. In line with our
previous observation,29 treating cells with 50 ng/mL TNFα
for 22 h increased cell permeability to 2.4-fold of controls
(Figure 3A). MC4 showed an inhibitory effect on TNFαstimulated cell permeability at all concentrations of 30, 3,
and 0.3 nM, and at the lowest concentration of 0.3 nM, MC4
exerted the best inhibitory effect, which was 1.2±0.2-fold
of untreated cells (P=0.005). Although FK866 also showed
an inhibitory effect, the permeability at the lowest level of
0.3 nM was 1.57±0.29-fold of untreated cells, which was
much higher than MC4 at the same concentration (P=0.053).
Our data suggested that both MC4 and FK866 decreased
the TNFα-induced HMVEC-L cell permeability, but MC4
showed more potent inhibitory effect.
To strengthen the findings that MC4 at 0.3 nM is a
stronger inhibitor than FK866 on TNFα-induced cell permeability, we measured the effects of MC4 and FK866 on
transendothelial electrical resistance (TER) in thrombintreated HMVEC-L (Figure 3B). Pretreatment with either
MC4 (0.3 nM) or FK866 (0.3 nM) attenuated HMVEC-L
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Figure 3 Inhibitory effects of MC4 and FK866 on TNFα- or thrombin-stimulated permeability in HMVEC-L monolayers.
Notes: HMVEC-L were seeded and cultured overnight in growth medium, the monolayers were starved for serum for 2 h, then pretreated with indicated concentrations
of MC4 (MC) or FK866 (FK) for another 2 h, followed by treatment with 50 ng/mL of TNFα (A) or 0.05 unit/mL of thrombin (B). (A) After 22 h, FITC–dextran reagent
was added into each insert for 20 min at room temperature. Leakage of FITC–dextran into the bottom chamber was assayed using in vitro cell permeability assay kit.
(B) Representative figure of three separate experiments of transendothelial electric resistance (TER) data from ECIS analysis of HMVEC-L cells treated with thrombin
(0.05 units/mL) with or without a pretreatment with 0.3 nM of MC4 or FK866. Results from each group are presented as mean ± SD of three samples from three separate
experiments, #P,0.01 vs control; **P,0.01 vs TNFα-treated cells.
Abbreviations: MC4, meta-carborane-butyl-3-(3-pyridinyl)-2E-propenamide; TNFα, tumor necrosis factor α; HMVEC-L, human lung microvascular endothelial cells; FITC,
fluorescence isothiocyanate; TER, transendothelial electric resistance; ECIS, electrical cell–substrate impedance sensing; SD, standard deviation.
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MC4 showed inhibitory effects on TNFα-induced cytokine
expression in a concentration-dependent manner. FK866
showed inhibitory effects only at the higher concentrations
(3 and 30 nM, P,0.05), while no inhibitory effect was
observed at the lowest concentration (0.3 nM) (Figures 4A
and 4B). No significant inhibition was observed for NAMPT
expression by MC4 or FK866 treatment.
To corroborate our RT-PCR results (Figures 4A and 4B),
ELISA was conducted to assay IL6 expression at the protein
level in A549 cells. As expected, compared with untreated
controls, TNFα (50 ng/mL) treatment elevated the intracellular IL6 level from 207±16.3 to 361±17.2 pg/mL (P=0.013).
Pretreatment with MC4 for 2 h, at concentrations of 30, 3, and
0.3 nM prior to TNFα treatment, decreased the upregulation
of IL6 levels to 275±30.4, 248±8.1, and 234±21.4 pg/mL,
respectively, which are higher than untreated control, but
significantly lower than cells treated with TNFα alone,
P=0.037, P=0.014, and P=0.027, respectively. The IL6 levels
in the cells pretreated with three concentrations of FK866

Effects of MC4 and FK866 on TNFαinduced cytokine expressions in A549
cells
Since our previous data demonstrated that NAMPT plays
a key role in pulmonary epithelial barrier dysfunction via
its regulation of cytokines,29 we measured the effects of
MC4 and FK866 on TNFα-induced cytokine expressions
in A549 cells by performing semi-quantitative RT-PCR
analyses of IL6, IL8, IL16, NAMPT, and CCR3 expression
in A549 cells. Serum-starved A549 cells were pre-treated
with three different concentrations of MC4 and FK866 prior
to a 5 h treatment with TNFα (50 ng/mL) (Figure 4). MC4
and FK866 showed inhibitory effects on TNFα-induced
cytokine expression at the mRNA level (Figures 4A and 4B).
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from the thrombin (0.05 units/mL)-induced reduction
in TER (Figure 3B). While both MC4 and FK866 were
effective, MC4 was more potent in blocking the effect of
thrombin.
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Figure 4 Effects of MC4 and FK866 on TNFα-induced cytokine expressions in A549 cells.
Notes: After serum-free starvation for 2 h, A549 cells (3×105) were incubated with indicated concentrations of MC4 and FK866 for 2 h, then treated with MC4 (MC) or
FK866 (FK) together with 50 ng/mL TNFα (T) for an additional 5 h. (A) A representative gel image of IL6, IL8, IL16, CCR3, NAMPT, and β-actin mRNA levels measured by
semi-quantitative RT-PCR. (B) Densitometry analysis of TNFα-induced cytokine mRNA levels normalized with β-actin and untreated controls. (C) Intracellular IL6 levels
were assayed using an intracellular IL6 ELISA kit. Results from each group are presented as mean ± SD of three samples from three separate experiments. #P,0.01 vs
untreated control; *P,0.01, **P,0.001 vs TNFα-treated cells.
Abbreviations: MC4, meta-carborane-butyl-3-(3-pyridinyl)-2E-propenamide; TNFα, tumor necrosis factor α; IL, interleukin; NAMPT, nicotinamide phosphoribosyltrans
ferase; mRNA, messenger RNA; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; RT-PCR, reverse transcription polymerase chain reaction; Cntl, control.
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prior to treatment with TNFα were 312±29.9, 311±34.8, and
332±22.4 pg/mL, which were lower than cells only treated
with TNFα (P=0.041, P=0.047, and P=0.42, respectively),
but much higher than cells pretreated with MC4 prior to
TNFα, suggesting that MC4 showed stronger inhibitory
effects on TNFα-induced IL6 expression in A549 cells than
FK866 (Figure 4C).

Inhibitory effects of MC4 and FK866 on
TNFα-induced intracellular NAD/NADH
levels in A549 cells
Since MC4 and FK866 are inhibitors of NAMPT, a key
enzyme in the mammalian salvage pathway for NAD synthesis, we assayed the total intracellular NAD plus NADH
concentrations in treated A549 cells. TNFα at a concentration
of 50 ng/mL increased NAD/NADH levels, while MC4 and
FK866 showed inhibitory effects in this process (Figure 5).
Treatment of A549 cells with TNFα for 20 h increased
NAD/NADH levels 1.49±0.2-fold relative to untreated cells.
Pretreatment with both small-molecule inhibitors at 3 and
30 nM resulted in NAD/NADH levels significantly below
non-TNFα-treated control cells. At 0.3 nM, MC4 was able to
significantly decrease the NAD/NADH levels (0.67±0.1-fold)
relative to the TNFα-treated controls (P=0.007). Although
FK866 also inhibited NAD/NADH levels (0.81±0.71-fold,
P=0.04), it was not a strong inhibitor as MC4 at this concentration (Figure 5).
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Inhibitory effects of MC4 and FK866
on TNFα-induced phosphorylation and
translocation of NFκB
TNFα activates the NFκB pathway by regulating the phosphorylation of NFκB, the key step in the initiation of the
translocation of NFκB from the cytoplasm to the nucleus.30
Therefore, we explored the inhibitory effects of MC4 and
FK866 on TNFα-induced phosphorylation of NFκB and
translocation of NFκB from cytoplasm into nuclei. Western
blot analysis showed that TNFα increased phosphorylation of
NFκB (Figures 6A and 6B). Phospho-NFκB was elevated by
4.7-fold relative to the untreated control. However, pretreatment with MC4 and FK866 at higher concentrations (3 and
30 nM) inhibited TNFα-induced phosphorylation of NFκB.
MC4 at a concentration as low as 0.3 nM also inhibited
TNFα-induced phospho-NFκB, which was 0.54±0.1-fold
of TNFα-treated controls (P=0.004), while the phosphoNFκB level in cells pretreated with 0.3 nM FK866 was
0.72±0.2-fold of TNFα-treated controls (P=0.03). There was
no obvious change observed in NFκB expression in treated
and untreated cells (Figures 6A and 6B).
The block of TNFα-induced NFκB translocation in A549
cells by MC4 and FK866 was also observed by an immunofluorescent assay (Figure 6C). In untreated A549 cells,
nuclear NFκB was detected in only 9%±1.4% of the cells,
while after treatment with 20 ng/mL of TNFα for 20 min,
nuclear NFκB was detected in 83%±4.3% of cells, suggesting that TNFα greatly induced the nuclear translocation of
NFκB. When the cells were pretreated with 0.3 nM MC4 and
FK866 for 2 h, TNFα-induced translocation was decreased
to 67.2±4.1 (P=0.037) and 36.4±2.7 (P=0.007), respectively
(Figure 6C), with MC4 providing greater inhibition of NFκB
translocation than FK866 (0.3 nM).



Discussion and conclusion
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Figure 5 Inhibitory effects of MC4 and FK866 on TNFα-induced intracellular NAD/
NADH levels in A549 cells.
Notes: A549 cells (3×105) were starved for 2 h, then pretreated with indicated
concentrations of MC4 and FK866 for 2 h, followed by indicated concentrations of
MC4 (MC) and FK866 (FK) together with 50 ng/mL of TNFα treatment for 20 h; the
intracellular NAD/NADH levels were tested. Results from each group are presented
as mean ± SD of three samples from three separate experiments. Bars are mean ± SD,
#
P,0.01 vs untreated controls, *P,0.05, **P,0.01 vs TNFα-treated cells.
Abbreviations: MC4, meta-carborane-butyl-3-(3-pyridinyl)-2E-propenamide; TNFα,
tumor necrosis factor α; NAD, nicotinamide adenine dinucleotide; SD, standard
deviation; Cntl, control.
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In this study, we have provided new and robust evidence
that our newly developed NAMPT inhibitor, MC4, had
much stronger anti-inflammatory effects than FK866.
In vivo studies supported that MC4 was a stronger inhibitor of CLP-induced sepsis in C57 BL/6J mice than FK866.
MC4-treated mice had lower mortality, lower serum TNFα
levels, lower lung MPO activity, lower lung expression of
inflammatory cytokines (IL1β and IL6), and milder lung
injuries than the FK866-treated group. In vitro cell culture
experimental results dovetail well with the in vivo findings
that MC4 displayed more potent inhibitory effects on the
TNFα-induced upregulation of inflammatory cytokines
such as IL6, IL8, CCR3, and IL16 in A549 cells, a lung
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Figure 6 Effects of MC4 and FK866 on TNFα-induced phosphorylation of NFκB and translocation of NFκB from cytoplasm into the nucleus in A549 cells.
Notes: A549 cells (3×105) were starved for 2 h, then pretreated with indicated concentrations of MC4 or FK866 for 2 h, followed by indicated concentrations of MC4 (M) or
FK866 (F) together with 50 ng/mL of TNFα treatment for 20 h. (A) Western blot analysis of the effects of MC4 and FK866 on TNFα-induced phosphorylation of NFκB.
(B) Densitometry analysis of TNFα-induced expression of p-NFκB normalized with GAPDH and untreated controls. (C) Representative immunofluorescent images showing
the effects of MC4 and FK866 on TNFα-stimulated translocation of NFκB. A549 cells were pretreated with 0.3 nM of either MC4 or FK866 for 2 h, then incubated with
20 ng/mL TNFα for 20 min. NFκB antibody was indirectly labeled with Alexa Fluor 488 secondary antibody (green), and cells were mounted with VECTASHIELD Mounting
Medium with DAPI (blue). (D) Percentage of cells with nuclear translocation of NFκB. A total of 400–500 cells were counted from randomly selected microscope fields
of each slide, and the percentage of cells with nuclear translocation of NFκB was calculated. Data are representative of three separate experiments. Bars are mean ± SD,
#
P,0.01 vs control; *P,0.05, **P,0.01 vs TNFα-treated cells.
Abbreviations: MC4, meta-carborane-butyl-3-(3-pyridinyl)-2E-propenamide; TNFα, tumor necrosis factor α; NFκB, nuclear factor kappa B; SD, standard deviation;
Cntl, control.

alveolar type II epithelial cell line, than FK866. Our finding
represents the first study to evaluate NAMPT inhibitionbased preclinical therapy of CLP-induced sepsis in mice.
Our results support MC4 as a potential therapeutic agent
for sepsis.
Both FK866 and MC4 decreased CLP-induced mortality
(Figure 1A). Statistical analysis by the Kaplan–Meier method
demonstrated that MC4 significantly decreased mortality
(Breslow test, P=0.043), while testing logrank showed an
approaching significance (P=0.077). Both the Breslow and
logrank tests did not show a significant difference in survival
between FK866 and control groups.
When comparing between prophylactic and therapeutic
treatments of both FK866 and MC4, we found that the
magnitude of the difference in the inhibitory effect on
CLP-induced sepsis was larger in prophylactic experiments
(Figures 1B and 2A). That may be due to the frequency and
dose of drug administration. The prophylactic treatment
involved administration of FK866 or MC4 three times prior
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to CLP, while the therapeutic treatment was a single dose of
the drugs. Nevertheless, histological examination solidified
our initial findings that MC4 was a more potent inhibitor
of mouse lung injury induced by CLP than FK866. MC4,
as shown by H&E staining, more strongly attenuated CLPinduced acute lung injuries, including less alveoli filled
with proteinaceous fluid, milder septal thickening, and less
interstitial lymphocytic infiltrates, than FK866 compared to
the control DMSO-treated mice (Figures 2B and 2C).
Mechanistically, we found that MC4 inhibited NFκB
phosphorylation and translocation from cytoplasm to nucleus
better than FK866 (Figure 6). NFκB is central to the innate
immunity response.31 The vertebrate inflammatory response
is the most obvious manifestation of innate immunity.31
Deregulation of NFκB is a hallmark of chronic inflammatory
diseases.32 In most cell types, the inactive p50/p65 NFκB
heterodimer is located in the cytoplasm, complexed to its IκB
inhibitory unit. Stimulation of cells by various reagents, such
as bacterial endotoxins or cytokines, phosphorylates NFκB,
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Drug Design, Development and Therapy downloaded from https://www.dovepress.com/ by 99.28.59.98 on 26-Oct-2019
For personal use only.

Dovepress

which leads to a dissociation of NFκB from IκB and a rapid
translocation of free NFκB to the nucleus where it induces
hundreds of genes, including many inflammatory cytokines.31
Thus, it can be safely reasoned that the inhibitory effect by
MC4 on CLP-induced sepsis, pulmonary inflammation, and
pulmonary cell cytokine expressions was due to its inhibition
of NFκB activation. Our comparative study also revealed
that MC4 inhibits TNFα-mediated NAD+ and NADH levels
better than FK866 in A549 cells (Figure 5). It has been well
established that NAMPT is a key enzyme in the eukaryotic
cell NAD synthesis of mammalian salvage pathway.33,34 Our
findings in this study are consistent with our previous finding
that MC4 exhibits 100-fold increase in NAMPT inhibition
than FK866.21 This explains the stronger inhibitory effect of
MC4 on cell NAD synthesis than FK866. Van Gool et al18
reported that intracellular NAD levels regulate TNF protein
synthesis via Sirt6, a member of the NAD-dependent sirtuin
family. We surmise that TNFα induced upregulation of cell
NAD synthesis via its upregulation of NAMPT. Because
MC4 had a stronger inhibitory effect on NAMPT, it led to
a greater inhibition of TNFα-mediated NAD+ and NADH
levels in A549 cells than FK866. It is recognized that NAD+
biosynthesis through NAMPT holds potential as a target
for the treatment of inflammatory disorders due to the role
of NAD+ in immune cell signaling and metabolism. Thus,
the attenuation of MC4 of CLP-induced sepsis, pulmonary
inflammation, and pulmonary cell cytokine expressions
may lie at its more effective inhibition of NAD synthesis
catalyzed by NAMPT. However, this may not be the whole
picture. Our previous study reported the regulation of
inflammatory cytokine expression in pulmonary epithelial
cells by pre-B-cell colony-enhancing factor (PBEF, another
name of NAMPT) via a non-enzymatic and AP-1-dependent
mechanism.35 Li et al36 also reported that extracellular PBEF
protected macrophages from endoplasmic reticulum stressinduced apoptosis by activating an IL6/STAT3 signaling
pathway via a non-enzymatic mechanism of NAMPT. Malam
et al37 demonstrated that priming for neutrophil respiratory
burst by PBEF (NAMPT) occurred independently of its
NAD-generating capacity because neither NM nor NAD
could recapitulate the effects and, furthermore, that FK866
could not inhibit priming. Based on these observations,
we posit that MC4 may have a higher binding affinity to
NAMPT than FK866, which leads to a more severe distorted
conformation, resulting in structural constraints not favorable to the interaction of NAMPT with its elusive receptor
or other key proteins. The engendered consequence would
be a diminished cytokine activity of NAMPT. Whether this

Drug Design, Development and Therapy 2017:11

MC4 is a more potent NAMPT inhibitor than FK866

non-enzymatic mechanism is operative here warrants further
investigation.
Furthermore, our experiments demonstrated that MC4
was a more potent inhibitor of TNFα-induced HMVEC-L
permeability and thrombin-induced decreases of transendothelial electric resistance in HMVEC-L, a cell barrier
function indicator, than FK866 (Figure 3). TNFα and
thrombin are known inducers of vascular endothelial
permeability.29,38,39 Presumably, MC4 attenuated the stimuliinduced permeability better than FK866 via its stronger
inhibition of NAMPT functions and hence, corresponding
suppression of stimuli-induced signal transduction pathways.
These observations can also explain fewer lung neutrophil
infiltrates (Figure 2C) as indicated by lower lung MPO
activity (Figure 1C) in the MC4-treated group compared
with the FK866-treated group.
Both MC4 and FK866 decreased pro-inflammation
cytokine mRNA expression in A549 cells but did not
downregulate NAMPT mRNA significantly (Figure 4B).
This may be explained by the feature that both chemicals
bind the two active sites of NAMPT homodimers, leading
to the inhibition of its enzymatic activity21 rather than the
inhibition of NAMPT expression. Less neutrophil infiltration
and milder lung injury in the MC4-treated mice than in the
FK866-treated mice (Figure 2) may be in part ascribed to the
stronger inhibitory effect of MC4 on NAMPT, causing more
apoptosis of neutrophils and hence less numbers and duration
of neutrophil infiltrates into the lung tissues.
Sepsis is a major cause of death in intensive care units
worldwide, with mortality rates ranging from 20% for
sepsis, through 40% for severe sepsis, to .60% for septic
shock.40,41 This is because the molecular pathogenesis of
sepsis is still incompletely understood and its specific and
effective therapies are lacking. NAMPT is emerging as a
potential new therapeutic target in sepsis. Jia et al15 first
reported that NAMPT mRNA in neutrophils from critically
ill septic patients was expressed at higher levels than those
in controls. Our previous study discovered that a susceptible
haplotype GC in the promoter of human NAMPT gene had
a 4.84-fold higher risk of sepsis, while a potential protective haplotype TT had a lower risk of sepsis in a Caucasian
patient population.7 Bajwa et al replicated and extended our
findings that the NAMPT-1001T.G variant allele and related
haplotype were associated with increased odds of developing
acute respiratory distress syndrome (ARDS), which is frequently associated with severe sepsis, and increased hazard of
intensive care unit mortality among at-risk patients, whereas
the -1535C.T (originally labeled as -1543C.T) variant
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allele and related haplotype are associated with decreased
odds of ARDS among patients with septic shock and better
outcomes among patients with ARDS.42 These results suggest that NAMPT is a biochemical and genetic marker to
sepsis. Thus, NAMPT may represent a viable therapeutic
target to sepsis. Although there are some limitations on this
study, such as failing to compare the side effects between
two inhibitors in mice, failing to explore the best option of
drug administration routes in mice, and failing to gain systematically into underlying molecular mechanisms, our study
has provided nine lines of solid evidence, including serum
TNFα levels, pulmonary cytokine expression, lung histology,
and MPO activity in a mouse model of sepsis, as well as
pulmonary A549 cell cytokine expression, HMVEC-L cell
permeability, HMVEC-L TER, NFκB phosphorylation, and
nuclear translocation, which all support that small chemical
NAMPT inhibitors MC4 and FK866 can attenuate sepsisinduced systematic and pulmonary inflammation and that
MC4 is a significantly more potent inhibitor than FK866.
Considering that FK866 displayed dose-limiting side effects
of thrombopenia and bleeding in clinical trials,20 MC4, in
which a carborane has replaced the benzoylpiperidine moiety
of FK866, may reduce or attenuate this potential side effects
of thrombopenia and bleeding since the benzoylpiperidine
could be a toxic-causing component.21 Previous works
have demonstrated that carboranes are potentially valuable
pharmacophores owing to their hydrophobicity, extensively
developed chemistry, and high biostability. 43 Our study
prompts us to reason that MC4 could be a viable therapeutic
alternative for clinical application because of its lower effective dosage and presumed fewer side effects, which will be
verified by in vivo animal studies.
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